Accepted at 2:22 p.m. Jul, 07, 2025 by jaynguyen
Author: michellemili
Co-authors: jaynguyen
Related Note: 1689433828580
Rationale for change

The FDA label for spironolactone includes a warning about tumorigenicity based on high-dose animal studies, but human data do not support an increased risk of breast cancer, and current clinical guidelines do not list a history of breast cancer as a contraindication. It carries no black boxed warning for a history of breast cancer

Text Text
Extra Extra
Personal Notes
Empty field
Missed Questions
Empty field
DermPath
Empty field
Dermoscopy
Empty field
VisualDx
Empty field
DermNet
Empty field
Full Spectrum of Dermatology
Empty field
Dermnemonics
Empty field
Dermatographix
Empty field
Textbook
Empty field
Additional Resources
Empty field
One by one
Empty field
#Dermki::AAD_Basic_Curriculum::Week_1::Acne_and_Rosacea #Dermki::Alikhan::03_General_Derm::03.13_Follicular_&_eccrine/apocrine_disorders AnkiHub_Subdeck::Dermki::03_General_Dermatology